ImmuCell (NASDAQ:ICCC) Stock Passes Above 200-Day Moving Average - Here's What Happened

Key Points

• ImmuCell's stock recently crossed above its 200-day moving average of $6.04, reaching a high of $6.83 before closing at $6.59.
• The company reported a net margin of 6.23% and earnings per share of $0.06 for the last quarter, with revenues totaling $6.45 million.
• Institutional ownership of ImmuCell stands at 13.47%, with Geode Capital Management recently increasing its stake by 4.2%.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.04 and traded as high as $6.83. ImmuCell shares last traded at $6.59, with a volume of 27,486 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a "hold (c-)" rating on shares of ImmuCell in a research note on Wednesday. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold".

ImmuCell Trading Up 2.2%

The firm has a market cap of $59.64 million, a PE ratio of 34.69 and a beta of 0.30. The business has a 50-day moving average price of $6.22 and a two-hundred day moving average price of $6.04. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.85 and a quick ratio of 1.99.

ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The business had revenue of $6.45 million during the quarter.

Institutional Trading of ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC lifted its stake in shares of ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 71,852 shares of the biotechnology company's stock after acquiring an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. 13.47% of the stock is currently owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.